Clinical trials: Immunologic Memory
- Condition Immunologic Memory
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Severe Hemophilia A With Inhibitor
Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors
This is an observational, prospective, longitudinal, multicenter, cohort study designed with the scope to verify whether or not TGA may predict effectiveness of different FVIII concentrates class (devoid or rich of VWF) in…
- Trial name
- PredicTGA (NCT01505946)
- Testing
- TGA (Thrombin generation Assay)
- Where
- 15 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Grifols Italia S.p.A
Prevention of Meningococcal Disease
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
The purpose of this study is to evaluate the safety, immunogenicity and induction of immune memory after two or three doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy infants.
- Trial name
- NCT00262002
- Testing
- MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation), MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation), MenACWY PS (MenACWY-CRM, polysaccharide vaccine)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Prophylaxis Pneumococcal Vaccine
Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)
Evaluate the immunological memory induced by 4 doses of GSK Biologicals' 11valent pneumococcal vaccine; study antibody persistence 30 months after the 4 dose vaccination with GSK Biologicals' 11-valent pneumococcal vaccine in…
- Trial name
- NCT00169507
- Testing
- Pneumococcal (vaccine)
- Where
- 4 sites in Slovakia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prevention of Meningococcal Infection
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in healthy children
- Trial name
- NCT00311415
- Testing
- Meningococcal C conjugate vaccine
- Where
- 2 sites in Germany, Poland
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines